Build with Axial: https://axial22.axialvc.com/
Get these analyses to your inbox — https://axial.substack.com/
Axial partners with great founders and inventors. We invest in early-stage life sciences companies often when they are no more than an idea. We are fanatical about helping the rare inventor who is compelled to build their own enduring business. If you or someone you know has a great idea or company in life sciences, Axial would be excited to get to know you and possibly invest in your vision and company . We are excited to be in business with you — email us at info@axialvc.com
Recursion is a one of the canonical AI drug discovery businesses. Founded in 2013 by Chris Gibson, Blake Borgeson, and Dean Li, the company spun out of the University of Utah to industrialize drug development. In conjunction with “The Business of AI in Life Sciences,” this case study is focused on understanding the key drivers for Recursion’s success and the long-term potential of their platform and business model.
An important theme for Recursion that shouldn’t be discounted is being in the right place at the right time. Gibson was an MD/PhD student at the University of Utah where we did his research on cerebral cavernous malformations (CCM). The only reason he moved out to Utah was due to his wife doing her medical residency in Salt Lake City. Chris then joined Dean Li’s lab who is well known for world-class medical research and had already spun off several companies in the past…
